Arcturus Therapeutics Holdings Inc. (ARCT) Stock Score, Valuation & Financial Research
Arcturus Therapeutics Holdings Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 26/100.
Quick answer for ARCT
Arcturus Therapeutics Holdings Inc. currently has a Wall Street Score of 26/100. The stored market price is $15.6. Its financial score is 39/100. Its valuation score is 0/100. The latest WSS change is -0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Arcturus Therapeutics Holdings Inc. does
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG,
ARCT financial snapshot
- Wall Street Score:
- 26/100
- Current price:
- $15.6
- Market capitalization:
- $443.4M
- Revenue:
- $23.8M
- Net income:
- $-93.3M
- Free cash flow:
- $-74.5M
- Cash:
- $191.5M
- Total debt:
- $22.9M
- EPS:
- -3.33
- Financial score:
- 39/100
- Valuation score:
- 0/100
- Revenue score:
- 1/100
What stands out
- Reported year-over-year revenue growth is -0.6%.
- Free cash flow is $-74.5M, showing cash burn in the current stored period.
- The balance sheet shows $191.5M of cash versus $22.9M of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -0.1 points: ARCT decreased 0.1 points because some fundamentals weakened.
- The current research record carries a missing opportunity history warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 39/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ARCT
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.